Biotricity announces the launch of its direct-to-consumer heart health screening program, HeartSecure. Someone in the world dies of cardiovascular disease every 1.5 seconds. In the U.S. alone, 127 million adults have at least 1 risk factor for heart disease, and 1 out of every 3 deaths is attributed to heart disease. To encourage preventative heart care and help reduce the prevalence of CVD, Biotricty is providing a limited-time discounted launch offer for HeartSecure. Early detection of heart disease and prompt intervention can slash the risk of heart attack and stroke by over 80%. A shortage in resources and cardiac professionals, an increasing chronically ill aging population, and limitations of insurance carriers, have led to an average wait time of about 1 month for a heart health screening with a cardiologist. HeartSecure reduces these barriers to provide a seamless and affordable solution for proactive cardiac health management. This innovative service is designed to meet the critical and escalating demand for accessible, timely cardiac health screening.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BTCY:
- Biotricity sees 2024 revenue growth exceeding 24% year-over-year
- Biotricity to launch direct-to-patient cardiac screening service HeartSecure
- Biotricity files to sell 1.42M shares of common stock for holders
- Biotricity files $50M mixed securities shelf
- Biotricity announces partnerships with home-based diagnostic companies
